Indications
Luveris in association with a follicle-stimulating-hormone (FSH) preparation is recommended for the stimulation of follicular development in women with severe luteinising-hormone (LH) and FSH deficiency. In clinical trials, these patients were defined by an endogenous serum LH level <1.2 IU/l.
Composition
- Active substance
- lutropin alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Luveris
- Active substance
- lutropin alfa
- ATC code
- G03GA07
- Therapeutic area
- Ovulation Induction, Infertility, Female
- Marketing authorisation holder
- Merck Europe B.V.